(a) High-resolution 3D MRI brain vascular map using SAIO. Various blood vessels in the rat brain can be visualized. In addition to clinically important brain vessels including anterior cerebral artery, middle cerebral artery, posterior cerebral artery, fine vessel structures as thin as ~ 100 microns in diameter can be clearly visualized. (b) 3D MRI brain vascular map using Dotarem (gadolinium-based contrast agent). Resolution is low and microvessels are not visible. (c) For 3D reconstruction, multiple slices of MRI images of the rat heart were obtained after injection of SAIO. Rat coronary arteries (180 microns) which are 10 times thinner than human coronary arteries were successfully visualized. Coronary arteries supply blood to the heart muscle and the blockage or narrowing of such arteries causes myocardial infarction or angina, but visualizing these arteries was impossible due to the limited resolution of current MRI contrast agents. Image courtesy of Institute for Basic Science
Study of Over 600,000 Women Shows Almost Half Are Getting The Wrong UTI Treatment
2 MARCH 2021
Across the United States, in both rural and urban settings, most women with private health insurance are receiving inappropriate treatment for their urinary tract infections (UTIs), according to a new study.
Of the 670,450 women included in this research, all of whom had been diagnosed with uncomplicated UTIs between the ages of 18 and 44, nearly half received the wrong antibiotics and over three quarters were prescribed the medicine for too long. (A UTI is declared uncomplicated when the patient has no abnormality or disease that could predispose them to more frequent infections.)
Published: Feb 23, 2021
PHILADELPHIA (BUSINESS WIRE) Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced that Adam Dinerman, Ph.D. and John Liu, Ph.D. have joined the company as Executive Director, Head of Chemistry, Manufacturing and Controls (CMC) and Vice President, Biology, respectively.
“The addition of top talent with deep functional experience is a critical success driver for Aro as we enter our next phase of growth,” stated Sue Dillon, Ph.D., co-founder and Chief Executive Officer of Aro Biotherapeutics. “We are very excited that Adam and John are joining our company, and are confident that they will both add tremendous value to our organization as our pipeline and platform continue to advance.”
Getty images
Most diabetes patients have either type 1, which is managed with insulin injections, or type 2, treated with other medications. Researchers at Washington University School of Medicine in St. Louis are part of a national research network aiming to discover rare forms of diabetes as a first step toward providing more effective treatments for forms of the disorder that don t fit neatly into either type 1 or type 2.
Washington University School of Medicine in St. Louis is part of a national research network aiming to discover rare forms of diabetes as a first step toward providing more effective treatments.
Most patients diagnosed with diabetes have either type 1, which is managed with insulin injections because patients can’t make their own insulin, or type 2, in which patients either don’t make enough insulin or don’t respond well to the insulin their bodies produce. People with type 2 diabetes are treated with medications.
COVID-19 can kill heart muscle cells, interfere with contraction eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.